Home LiteratureArticle Details
PMID: 17904654 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Genetically delivered antibody protects against West Nile virus.

Antiviral research ·Vol. 77 ·No. 1 ·2008-01-00 ·Pages 6-13

Pereboev A, Borisevich V, Tsuladze G, Shakhmatov M, Hudman D, Kazachinskaia E, Razumov I, Svyatchenko V, Loktev V, Yamshchikov V

Abstract

Gene-based delivery of recombinant antibody genes is a promising therapeutic strategy offering numerous advantages including sustained antibody levels, better safety profile and lower production cost. Here we describe generation of a recombinant antibody Fc-9E2 comprising a fusion protein between human Fc of IgG1 and a single-chain Fv derived from a hybridoma 9E2 secreting a mAb neutralizing West Nile virus (WNV). Fc-9E2 was shown to retain parental mAb's specificity and WNV-neutralizing capacity. Adenovirus-mediated in vivo delivery of the antibody gene resulted in sustained Fc-9E2 serum levels leading to abrogation of lethal WNV infection in an animal model.

MeSH Terms
Animals Antibodies, Monoclonal/immunology Antibodies, Viral/genetics,immunology Female Gene Transfer Techniques Humans Mice Mice, Inbred BALB C Recombinant Fusion Proteins/immunology West Nile Fever/immunology,prevention & control,virology West Nile virus/immunology
Chemicals
Antibodies, Monoclonal Antibodies, Viral Recombinant Fusion Proteins
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Pereboev Alexander
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham 35294-2172, USA. pereboev@uab.edu
Borisevich Viktoriya
Tsuladze George
Shakhmatov Mikhail
Hudman Deborah
Kazachinskaia Elena
Razumov Ivan
Svyatchenko Viktor
Loktev Valery
Yamshchikov Vladimir
References (41)
41 references, click to expand
  1. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee.
    Hum Gene Ther. 2002 Jan 1;13(1):3-13 PMID: 11779411
  2. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection.
    J Clin Microbiol. 2000 Jun;38(6):2232-9 PMID: 10834982
  3. Upregulation of signalase processing and induction of prM-E secretion by the flavivirus NS2B-NS3 protease: roles of protease components.
    J Virol. 1997 Jun;71(6):4364-71 PMID: 9151825
  4. FcRn: the MHC class I-related receptor that is more than an IgG transporter.
    Immunol Today. 1997 Dec;18(12):592-8 PMID: 9425738
  5. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus.
    Vaccine. 2005 Sep 15;23(39):4785-92 PMID: 15939510
  6. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
    Eur J Immunol. 1999 Sep;29(9):2819-25 PMID: 10508256
  7. Crystal structure of the West Nile virus envelope glycoprotein.
    J Virol. 2006 Dec;80(23):11467-74 PMID: 16987985
  8. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.
    Viral Immunol. 2003;16(3):259-78 PMID: 14583143
  9. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG.
    J Immunol. 1991 Oct 15;147(8):2657-62 PMID: 1833457
  10. Neutralizing monoclonal antibodies against Russian strain of the West Nile virus.
    Viral Immunol. 2005;18(3):558-68 PMID: 16212535
  11. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice.
    J Infect Dis. 2003 Jul 1;188(1):5-12 PMID: 12825165
  12. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development.
    Virology. 2004 Dec 5;330(1):304-12 PMID: 15527855
  13. Antibody prophylaxis and therapy for flavivirus encephalitis infections.
    Ann N Y Acad Sci. 2001 Dec;951:286-97 PMID: 11797785
  14. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.
    J Virol. 2002 Dec;76(24):13097-100 PMID: 12438639
  15. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.
    Nat Med. 2005 May;11(5):522-30 PMID: 15852016
  16. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
    J Immunol. 2000 Apr 15;164(8):4178-84 PMID: 10754313
  17. A surface expression vector for antibody screening.
    Gene. 1991 Aug 15;104(2):147-53 PMID: 1916287
  18. Characterization of neutralizing antibodies to West Nile virus.
    Virology. 2005 May 25;336(1):70-82 PMID: 15866072
  19. Isolation from human sera in Egypt of a virus apparently identical to West Nile virus.
    Proc Soc Exp Biol Med. 1951 Aug;77(4):661-5 PMID: 14891830
  20. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
    Mol Ther. 2005 Feb;11(2):237-44 PMID: 15668135
  21. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.
    J Immunol. 1985 Oct;135(4):2805-9 PMID: 4031501
  22. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.
    J Virol. 2005 Dec;79(23):14606-13 PMID: 16282460
  23. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
    Clin Cancer Res. 2000 Aug;6(8):3081-7 PMID: 10955787
  24. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12.
    Virology. 1968 Sep;36(1):115-25 PMID: 5669982
  25. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.
    J Virol. 2003 Dec;77(24):12941-9 PMID: 14645550
  26. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies.
    J Infect Dis. 2003 Jul 1;188(1):53-6 PMID: 12825170
  27. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report.
    Arch Virol. 1987;93(3-4):295-301 PMID: 3827600
  28. High level expression and secretion of Fc-X fusion proteins in mammalian cells.
    Protein Eng. 1998 Jun;11(6):495-500 PMID: 9725629
  29. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis.
    Emerg Infect Dis. 2002 Mar;8(3):245-51 PMID: 11927020
  30. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.
    J Virol. 2006 Dec;80(24):12149-59 PMID: 17035317
  31. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    J Mol Biol. 2007 May 4;368(3):652-65 PMID: 17362988
  32. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.
    J Virol. 2003 Dec;77(24):12931-40 PMID: 14645549
  33. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.
    J Virol. 2006 Jul;80(14):6982-92 PMID: 16809304
  34. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.
    J Virol. 2001 Aug;75(16):7769-73 PMID: 11462053
  35. Traditional and novel approaches to flavivirus vaccines.
    Int J Parasitol. 2003 May;33(5-6):567-82 PMID: 12782056
  36. Isolation of two strains of West Nile virus during an outbreak in southern Russia, 1999.
    Emerg Infect Dis. 2000 Jul-Aug;6(4):373-6 PMID: 10905970
  37. Therapeutic antibody gene transfer: an active approach to passive immunity.
    Mol Ther. 2004 Sep;10(3):411-6 PMID: 15336642
  38. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6179-85 PMID: 17062695
  39. A family of vectors for surface display and production of antibodies.
    Gene. 1993 Jun 15;128(1):97-101 PMID: 7685307
  40. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Cancer Gene Ther. 2002 Jul;9(7):553-66 PMID: 12082455
  41. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
    Cancer Res. 2007 Feb 1;67(3):871-5 PMID: 17283116
Article Info
Journal
Antiviral research
Abbr.
Antiviral Res
ISSN
0166-3542
DOI
10.1016/j.antiviral.2007.08.010
Email
pereboev@uab.edu
Published
2008-01-00
Epub
2007-00-14
Pages
6-13
Language
English
Region
Netherlands
NLM ID
8109699
PMCID
PMC2267767
Subset
IM
Grants
NIAID NIH HHS · R21 AI054538-01 · United States
NIAID NIH HHS · 1R01 AI049258 · United States
NIAID NIH HHS · 5R21 AI054538 · United States
NIAID NIH HHS · R21 AI054538 · United States
NIAID NIH HHS · 5U54 AI057157 · United States
NIAID NIH HHS · R03 AI053084 · United States
NIAID NIH HHS · 1R03 AI53084 · United States
NIAID NIH HHS · R01 AI049258-05 · United States
NIAID NIH HHS · U54 AI057157 · United States
NIAID NIH HHS · R03 AI053084-03 · United States
NIAID NIH HHS · U54 AI057157-05 · United States
NIAID NIH HHS · R01 AI049258 · United States
External Links
PubMed source DOI: 10.1016/j.antiviral.2007.08.010 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2